Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies

Cancer Chemotherapy and Pharmacology
G P SuttonH D Homesley

Abstract

Starting in July 1985, the Gynecologic Oncology Group conducted a series of phase II trials with ifosfamide/mesna in advanced or recurrent gynecologic malignancies. Previously untreated patients received 1.5 g/m2 i.v. ifosfamide daily for 5 days. Mesna was given i.v. q4h x 3 following ifosfamide; each dose was 20% of the daily ifosfamide dose. All patients with ovarian and 87% of those with cervical cancer had previously undergone platinum-based therapy. Because of the toxicity encountered in previously treated patients with ovarian carcinoma, the dose of ifosfamide was reduced to 1.2 g/m2 daily in all patients who had received prior chemo- or radiotherapy. In epithelial ovarian carcinoma, responses were observed in 8 (20.0%) of 41 evaluable patients, with 3 (7.0%) complete responses. Response duration was 2.1-20.3+ months, with a median of 6.9+ months. In squamous-cell carcinoma of the cervix, 3 (11.1%) of 27 evaluable patients showed partial responses of 1.8, 2.2, and 3.1 months' duration. Of 26 untreated patients with mixed mesodermal tumors of the uterus, 5 (19.2%) achieved complete and 3 (11.5%) showed partial responses, for an overall response rate of 30.7%. Response duration was 1.4(+)-8.6 months, with a median of 3.8 mo...Continue Reading

References

Nov 22, 1986·Lancet·M P GorenF E Pell
Jun 15, 1988·Journal of the National Cancer Institute·M Zalupski, L H Baker
Jan 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B M WheelerL H Einhorn
Mar 1, 1987·European Journal of Cancer & Clinical Oncology·V H BramwellR Sylvester
Jan 1, 1986·Cancer Chemotherapy and Pharmacology·R E ColemanC W Trask
Mar 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J LoehrerR Ansari

❮ Previous
Next ❯

Citations

Jan 1, 1991·Journal of Cancer Research and Clinical Oncology·W P BradeC E Araujo
Jan 1, 1995·La Revue de médecine interne·D Zylberait
Mar 18, 1999·Hematology/oncology Clinics of North America·C F VerschraegenH Fox
Nov 1, 1992·Acta Neurologica Scandinavica·O MerimskyS Chaitchik
Aug 1, 1992·American Journal of Obstetrics and Gynecology·G P SuttonD R Barnhill
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E ReedC E Myers
Nov 5, 2002·Best Practice & Research. Clinical Obstetrics & Gynaecology·Nelson Gustavo Neder Kalil, William Patrick McGuire
Sep 7, 2007·Gynecologic Oncology·Isabelle CadronIgnace Vergote
Aug 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jens-Uwe BlohmerPeter Schmid
Sep 1, 1991·Gynecologic Oncology·J P CurtinC P Morrow
Aug 10, 2011·Journal of Surgical Oncology·Masakuni NoguchiTakeo Kosaka
Sep 14, 2004·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·L R BiglerUNKNOWN Gynecologic Oncology Group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.